Anirban Maitra Highlights Ongoing and Planned RAS Inhibitor Combinations
Anirban Maitra highlighted a talk at NYU Langone Health on milestones in developing RAS tricomplex inhibitors. The presentation also covered ongoing and planned combination approaches.
Anirban Maitra shared a post on X about a talk on RAS tricomplex inhibitors at NYU Langone Health. He said the presentation covered milestones in developing RAS tricomplex inhibitors and the future, including combinations that are ongoing and planned.
Maitra, Director of the Perlmutter Cancer Center, said the talk was given by Mallika Singh from Revolution Medicines and was hosted by NYU GSOM Pathology chair Iannis Aifantis. He described it as “a walk down memory lane on milestones in developing RAS tricomplex inhibitors, and the future (combinations that are ongoing and planned).”